The most recent industry report from Future Market Insights estimates that the global nasal allergy treatments market sales will grow at a compound annual growth rate (CAGR) of 6.7% to reach an estimated valuation of US$ 13.3 billion in 2033. In 2022, the market was estimated to be worth US$ 6.6 billion.
Although allergies are frequent, their causes might differ from person to person. The allergen can be easily found with a diagnostic test. The incidence of nasal allergies among patients is high, and there is a low degree of awareness and information about them, according to the Journal of Family Medicine and Primary Care in 2020. The patient has a limited understanding of the causes, symptoms, effects, and management of nasal allergies. Patients’ knowledge of nasal allergies may be influenced by health education programs on the topic.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17114
In such circumstances, awareness is crucial, therefore webinars and campaigns aid in spreading the message. One such example is a health-focused week called allergy awareness week, which was established by the charity Allergy UK and is observed every year during a week chosen by the organization. It occurs in the year 2023 from April 24 to April 30. This week is dedicated to educating people about allergies and providing assistance and support to those who suffer from allergic disorders.
Key Takeaways:
- Allergic Rhinitis is the leading segment among other diseases, and holds around 65.8% market value share in 2022, owing to higher rates of identified cases.
- The tablets/Capsules segment is set to lead in terms of the form of nasal allergy treatment with a projected market value share of around 33.6% by 2033, with respect to the physical and chemical attributes.
- By prescription type, the widely adopted is OTC drugs as they are easily available without prescription and also the commonly prescribed drugs for allergy can be easily availed from drug stores. OTC by prescription type held a market share of 76.3% in the year 2022.
- Multiple treatments are available but Antihistamines hold a significant share of 46.0% in the treatment segment as they can successfully treat a wide range of allergic reaction symptoms.
- By distribution channel, hospital pharmacies held a share of around 35.9% in 2022 due to the easy accessibility of licensed and approved medications.
- North American region dominated the global market with the U.S. contributing 92.4%value share to the North American market, owing to the prevalence of nasal allergies in the region.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17114
“In light of the increasing demand for nasal allergy treatment and the increasing prevalence of allergies, the market for nasal allergy treatment is predicted to expand globally,“says an analyst at Future Market Insights (FMI).
Market Competition:
The market for nasal allergy treatment represents a fragmented market. The market players are focused on developing and launching drugs and attaining approvals in order to improve treatment outcomes. Manufacturers are also looking ahead to acquisition and collaborations.
- GlaxoSmithKline plc’s (GSK) Nucala (mepolizumab) received US Food and Drug Administration (FDA) on 29 July 2021. Nucala (mepolizumab) is a monoclonal antibody targeting interleukin-5 (IL-5). Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) can be treated using this drug.
- In April 2020, ALK Abello was pleased to share that Health Canada has approved once-daily ITULATEK, a sublingual tablet for the treatment of tree pollen allergy.
Key Players:
- Merck KGaA
- Johnson & Johnson
- Allergopharma
- Sanofi SA
- McNeil Consumer Healthcare,
- Genentech Inc.
- GlaxoSmithKline PLC
- Leti Pharma,
- Alerpharma S.A
- Allergan, Inc.
- Meda Pharmaceuticals, Inc
- Novartis International AG
- Bausch Health Companies Inc.
- Allergopharma
- ALK Abello
- Stallergenes Greer
- Allergy Therapeutics
- Aimmune Therapeutics
- Biomay AG
- HAL Allergy Group
- Bayer
- AstraZeneca
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the nasal allergy treatment market in its latest study, presenting a historical demand assessment of 2018 to 2022 and projections for 2023 to 2033. The global nasal allergy treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17114
The research study is based on the by disease – (allergic rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, non-allergic rhinitis, and infectious rhinitis), by form- (tablets/capsules, liquid, creams & lotions, drops, and spray) by prescription (OTC and prescription based), by route of administration- (oral, intranasal, sublingual, subcutaneous, and intravenous), by treatment (antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists), by distribution channel- (hospital pharmacies, supermarkets/hypermarkets, online pharmacies, retail pharmacies, speciality clinics, others), and across seven key regions of the world.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube